Search company, investor...
Gan & Lee Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


About Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals (603087.SH) is a biotechnology company in China engaged in the development, manufacturing, and commercialization of human therapeutics. Gan & Lee has fully integrated capabilities in research and development, manufacturing, commercial operations and product distribution. Its top line products recombinant human insulin and insulin analogs meet EP and USP quality standards, and it is the only local company which owns human insulin analogue in China.

Gan & Lee Pharmaceuticals Headquarters Location

No. 8 Jingsheng North 3rd Street Golden Bridge Science Industrial Base, Zhongguancun Science Park, Tongzhou District

Beijing, Beijing, 101102,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Gan & Lee Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Gan & Lee Pharmaceuticals in 1 CB Insights research brief, most recently on Jul 6, 2022.

Expert Collections containing Gan & Lee Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Gan & Lee Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,750 items

Gan & Lee Pharmaceuticals Patents

Gan & Lee Pharmaceuticals has filed 7 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Proteins
  • Cell cycle
patents chart

Application Date

Grant Date


Related Topics




Stereochemistry, Transcription factors, Pyridines, Nitriles, Amines


Application Date


Grant Date



Related Topics

Stereochemistry, Transcription factors, Pyridines, Nitriles, Amines



Latest Gan & Lee Pharmaceuticals News

Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion

Jul 11, 2022

News provided by Share this article Share this article SHANGHAI, July 10, 2022 /PRNewswire/ -- Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion, including USD Fund VIII at US$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million). As in prior funds, Fund VIII was oversubscribed and reached its hard cap for limited partner commitments. This increases the firm's capital raised to $9.4 billion across 18 funds. Committed capital includes the Qiming Venture Partners Fund VIII main fund that focuses on early and growth stage Technology and Consumer (T&C) and Healthcare investments and the Qiming Venture Partners Fund VIII-HC parallel healthcare fund that invests alongside the main fund (collectively "Fund VIII"). Fund VIII is led by Managing Partners Duane Kuang, Nisa Leung, William Hu, and Gary Rieschel, with full support of investment and administration teams based in Shanghai, Beijing, Shenzhen, and Hong Kong. Since its inception in 2006, Qiming has demonstrated its ability to deliver consistently strong venture capital returns in China. Qiming has backed over 480 fast-growing companies, over 70 of which have achieved unicorn status. A vast majority of these companies were early stage at the time of initial investment. In addition, over 180 of our portfolio companies have achieved exits through IPO, M&A or other means, including Xiaomi, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, APT Medical, Meituan, Bilibili and Roborock. About Qiming Venture Partners Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ: BILI , SEHK:9626), Zhihu (NYSE: ZH , SEHK: 2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ: ZLAB , SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ: SDGR ), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Venus MedTech (SEHK:2500), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), Yuanxin Technology, dMed-Clinipace, Belief BioMed, WeRide, Biren Technology and UBTech among many others. SOURCE Qiming Venture Partners

Gan & Lee Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Gan & Lee Pharmaceuticals Rank

  • When was Gan & Lee Pharmaceuticals founded?

    Gan & Lee Pharmaceuticals was founded in 1998.

  • Where is Gan & Lee Pharmaceuticals's headquarters?

    Gan & Lee Pharmaceuticals's headquarters is located at No. 8 Jingsheng North 3rd Street, Beijing.

  • What is Gan & Lee Pharmaceuticals's latest funding round?

    Gan & Lee Pharmaceuticals's latest funding round is IPO.

  • How much did Gan & Lee Pharmaceuticals raise?

    Gan & Lee Pharmaceuticals raised a total of $449.52M.

  • Who are the investors of Gan & Lee Pharmaceuticals?

    Investors of Gan & Lee Pharmaceuticals include Qiming Venture Partners, Wintersweet, Hillhouse Capital Management, Goldman Sachs, GL Capital and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.